Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Iveena Delivery Systems, Inc.
- Proposal award date
- 2017-09-30
- Contract end date
- 2018-09-29
- UEI
- EQ3KNDP93M27
- Solicitation number
- PA16-302
- Topic code
- N
Research abstract
Project Summary
Keratoconus KCN is a progressive disorder associated with structural changes in corneal collagen
organization that leads to corneal thinning and ruptures in Bowman s layer and or Descemet s membrane As
the disease progresses it leads to irregular astigmatism progressive myopia and subsequently poor visual
acuity Treatment options are surprisingly limited with no oral or topical pharmaceutical therapy Most mild KCN
can be corrected with glasses or soft contact lenses but very often patients will need toric or hard contacts as
the disease progresses Ultimately in patients will require surgery
Our technology is based on a co factor for lysyl oxidase LOX activity and that low LOX activity in the cornea
has been linked to the development of keratoconus both genetically and biochemically We provide the evidence
in preliminary results of a new topical eye drop effect on human keratoconus corneas in increasing both LOX
activity and cornea stiffening We also show the first morphological evidence of induced central corneal
flattening in rabbits with optical coherence tomography OCT Based on the current evidence base we outline
new proactive pathways for keratoconus management and enabling a non invasive and relatively cost effective
treatment for keratoconus
We propose a research plan under three specific aims that will a study the safety and tolerability of the eye
drops in rabbits in vivo b study the effect of dosing frequency on rabbit corneal shape and biochemical
crosslinking in vivo and c to determine whether the eye drops induce biochemical crosslinking on human
keratoconic corneas ex vivo Project Narrative
Keratoconus is a non inflammatory progressive thinning of the cornea that is usually bilateral and involves the
central two thirds of the cornea The thinning of cornea leads to irregular astigmatism progressive myopia and
subsequently poor visual acuity iVeena is proposing a new topical drug therapy for keratoconus The proposed
project has significance in terms of scientific relevance in elucidating a poorly understood disease condition
keratoconus and the potential for advancing ocular therapeutics for other corneal thinning disorders
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Research funding history
7 SBIR/STTR records share this UEI (2015–2025). Reported award amounts total $5,630,748. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, National Science Foundation
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards